Effector Therapeutics Stock Market Value
| EFTR Stock | USD 0.0002 0.0004 66.67% |
| Symbol | Effector |
Effector Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.57) | Revenue Per Share | Quarterly Revenue Growth 1.17 | Return On Assets | Return On Equity |
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Effector Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Effector Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Effector Therapeutics.
| 09/03/2025 |
| 12/02/2025 |
If you would invest 0.00 in Effector Therapeutics on September 3, 2025 and sell it all today you would earn a total of 0.00 from holding Effector Therapeutics or generate 0.0% return on investment in Effector Therapeutics over 90 days. Effector Therapeutics is related to or competes with Luckin Coffee, Everus Construction, Westrock Coffee, Black Rock, and Warner Music. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective transla... More
Effector Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Effector Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Effector Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1282 | |||
| Maximum Drawdown | 266.67 |
Effector Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Effector Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Effector Therapeutics' standard deviation. In reality, there are many statistical measures that can use Effector Therapeutics historical prices to predict the future Effector Therapeutics' volatility.| Risk Adjusted Performance | 0.0994 | |||
| Jensen Alpha | 5.91 | |||
| Total Risk Alpha | 2.6 | |||
| Treynor Ratio | (0.49) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Effector Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Effector Therapeutics Backtested Returns
Effector Therapeutics is out of control given 3 months investment horizon. Effector Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for nineteen different technical indicators, which can help you to evaluate if expected returns of 5.57% are justified by taking the suggested risk. Use Effector Therapeutics Mean Deviation of 16.18, variance of 1739.41, and Standard Deviation of 41.71 to evaluate company specific risk that cannot be diversified away. Effector Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -11.07, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Effector Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Effector Therapeutics is expected to outperform it. Use Effector Therapeutics mean deviation, jensen alpha, as well as the relationship between the Jensen Alpha and rate of daily change , to analyze future returns on Effector Therapeutics.
Auto-correlation | 0.22 |
Weak predictability
Effector Therapeutics has weak predictability. Overlapping area represents the amount of predictability between Effector Therapeutics time series from 3rd of September 2025 to 18th of October 2025 and 18th of October 2025 to 2nd of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Effector Therapeutics price movement. The serial correlation of 0.22 indicates that over 22.0% of current Effector Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.22 | |
| Spearman Rank Test | 0.84 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Effector Therapeutics lagged returns against current returns
Autocorrelation, which is Effector Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Effector Therapeutics' stock expected returns. We can calculate the autocorrelation of Effector Therapeutics returns to help us make a trade decision. For example, suppose you find that Effector Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Effector Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Effector Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Effector Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Effector Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Effector Therapeutics Lagged Returns
When evaluating Effector Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Effector Therapeutics stock have on its future price. Effector Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Effector Therapeutics autocorrelation shows the relationship between Effector Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Effector Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Effector Stock
| 0.68 | ALVO | Alvotech Downward Rally | PairCorr |
| 0.63 | OBI | Ondine Biomedical | PairCorr |
| 0.54 | OPTI | OptiBiotix Health Plc | PairCorr |
| 0.43 | AVH | Avita Medical | PairCorr |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Effector Stock Analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.